JP2018502884A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018502884A5 JP2018502884A5 JP2017538612A JP2017538612A JP2018502884A5 JP 2018502884 A5 JP2018502884 A5 JP 2018502884A5 JP 2017538612 A JP2017538612 A JP 2017538612A JP 2017538612 A JP2017538612 A JP 2017538612A JP 2018502884 A5 JP2018502884 A5 JP 2018502884A5
- Authority
- JP
- Japan
- Prior art keywords
- pain
- neuropathic pain
- chronic
- acute
- peripheral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000004296 Neuralgia Diseases 0.000 description 19
- 208000002193 Pain Diseases 0.000 description 12
- 230000001154 acute Effects 0.000 description 9
- 230000001684 chronic Effects 0.000 description 9
- 230000002093 peripheral Effects 0.000 description 8
- 206010062237 Renal impairment Diseases 0.000 description 4
- 208000001294 Nociceptive Pain Diseases 0.000 description 3
- 201000009673 liver disease Diseases 0.000 description 3
- 230000001473 noxious Effects 0.000 description 2
- 230000000392 somatic Effects 0.000 description 2
- AYXYPKUFHZROOJ-ZETCQYMHSA-N (3S)-3-(aminomethyl)-5-methylhexanoic acid Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N Amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 229960000836 Amitriptyline Drugs 0.000 description 1
- 210000000988 Bone and Bones Anatomy 0.000 description 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N Duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapen Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N Hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 1
- 210000003205 Muscles Anatomy 0.000 description 1
- 206010052639 Nerve injury Diseases 0.000 description 1
- 210000000929 Nociceptors Anatomy 0.000 description 1
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 1
- 210000000578 Peripheral Nerves Anatomy 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 208000004358 Polyneuropathy Diseases 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- 210000001138 Tears Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960002866 duloxetine Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 229960000240 hydrocodone Drugs 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 108091008022 nociceptors Proteins 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 229960005118 oxymorphone Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960001233 pregabalin Drugs 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000003238 somatosensory Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
Description
市販のアミトリプチリンのためにおよび市販のオキシモルフォンのために提供された情報によると、腎機能障害または肝機能障害を有する対象を治療する場合には、健康リスクを最小限にするために用量の減量が必要である。同様に、市販のヒドロコドンのために提供された情報によると、腎障害および重篤な肝障害を有する対象における用量減量が示されており、デュロキセチンは肝障害および重篤な腎障害において禁忌が示されている。また、プレガバリンおよびガバペンチンは腎障害を有する対象において用量調節が必要であることが報告されている。
侵害受容性疼痛は、刺激が筋肉、骨、皮膚または内部器官に組織損傷を引き起こした時に結果として生じる不快を表す。本明細書の目的に関して、侵害受容性疼痛は、有害な強度に迫るかまたはそれを超える刺激にのみ応答する末梢神経線維の刺激によって引き起こされ（侵害受容器）、有害刺激の様式に応じて分類することができ、最も共通するカテゴリーは、「熱」（熱または冷）、「機械的」（圧潰、引き裂く等）および「化学的」（切り傷にヨウ素、眼にチリパウダー）である。侵害受容性疼痛はまた、「内臓」痛、「深部体性」痛および「表在体性」痛に分類することもできる。
神経障害性疼痛は、神経損傷または神経機能異常に由来する疼痛である。好ましくは、神経障害性疼痛は、急性神経障害性疼痛および慢性神経障害性疼痛から選択される。神経障害性疼痛は、身体感覚に関与する神経系（体性感覚系）の中枢もしくは末梢部分に影響を及ぼす損傷または疾患により引き起こされ得る。好ましくは、本発明の剤形は、慢性神経障害性疼痛または急性神経障害性疼痛、末梢性神経障害性疼痛または中枢性神経障害性疼痛、単神経障害性疼痛または多発性神経障害性疼痛の治療における使用のためのものである。上記神経障害性疼痛が慢性である場合、それは慢性末梢性神経障害性疼痛または慢性中枢性神経障害性疼痛であり得、１つの好ましい実施態様において、慢性末梢性単神経障害性疼痛または慢性中枢性単神経障害性疼痛、他の好ましい実施態様において、慢性末梢性多発性神経障害性疼痛または慢性中枢性多発性神経障害性疼痛であり得る。上記神経障害性疼痛が急性である場合、それは急性末梢性神経障害性疼痛または急性中枢性神経障害疼痛であり得、１つの好ましい実施態様において、急性末梢性単神経障害性疼痛または急性中枢性単神経障害性疼痛、他の好ましい実施態様において、急性末梢性多発性神経障害性疼痛または急性中枢性多発性神経障害性疼痛であり得る。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562106845P | 2015-01-23 | 2015-01-23 | |
| US62/106,845 | 2015-01-23 | ||
| PCT/EP2016/000114 WO2016116280A1 (en) | 2015-01-23 | 2016-01-22 | Cebranopadol for treating pain in subjects with impaired hepatic and/or impaired renal function |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020036768A Division JP7138300B2 (ja) | 2015-01-23 | 2020-03-04 | 肝機能障害および／または腎機能障害を有する対象における疼痛を治療するためのセブラノパドール |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018502884A JP2018502884A (ja) | 2018-02-01 |
| JP2018502884A5 true JP2018502884A5 (ja) | 2020-01-16 |
| JP6673924B2 JP6673924B2 (ja) | 2020-03-25 |
Family
ID=55229644
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017538612A Active JP6673924B2 (ja) | 2015-01-23 | 2016-01-22 | 肝機能障害および／または腎機能障害を有する対象における疼痛を治療するためのセブラノパドール |
| JP2020036768A Active JP7138300B2 (ja) | 2015-01-23 | 2020-03-04 | 肝機能障害および／または腎機能障害を有する対象における疼痛を治療するためのセブラノパドール |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020036768A Active JP7138300B2 (ja) | 2015-01-23 | 2020-03-04 | 肝機能障害および／または腎機能障害を有する対象における疼痛を治療するためのセブラノパドール |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10022353B2 (ja) |
| EP (2) | EP3735970B1 (ja) |
| JP (2) | JP6673924B2 (ja) |
| CN (1) | CN107427493A (ja) |
| AU (1) | AU2016208779B2 (ja) |
| CA (1) | CA2974578C (ja) |
| DK (1) | DK3247352T3 (ja) |
| EA (1) | EA201791662A1 (ja) |
| IL (1) | IL253268A0 (ja) |
| MX (1) | MX2017009416A (ja) |
| TW (1) | TW201642853A (ja) |
| WO (1) | WO2016116280A1 (ja) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015119848A1 (en) | 2014-02-05 | 2015-08-13 | Merck Sharp & Dohme Corp. | Tablet formulation for cgrp-active compounds |
| DK3247352T3 (da) * | 2015-01-23 | 2020-09-07 | Gruenenthal Gmbh | Cebranopadol til behandling af smerter hos individer med forringet lever- og/eller forringet nyrefunktion |
| IT201700057899A1 (it) | 2017-05-29 | 2018-11-29 | Univ Degli Studi Di Camerino | Co-attivatori dei recettori MOP e NOP nel trattamento della dipendenza da droghe e/o psicostimolanti |
| WO2022140537A1 (en) * | 2020-12-22 | 2022-06-30 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| WO2024129782A1 (en) | 2022-12-12 | 2024-06-20 | Park Therapeutics, Inc. | Regimens and compositions useful for alleviating pain |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10252667A1 (de) | 2002-11-11 | 2004-05-27 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| DE102005016460A1 (de) | 2005-04-11 | 2006-10-19 | Grünenthal GmbH | Spriocyclische Cyclohexanderivate zur Behandlung von Substanzabhängigkeit |
| DE102006046745A1 (de) | 2006-09-29 | 2008-04-03 | Grünenthal GmbH | Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz |
| DE102007009319A1 (de) * | 2007-02-22 | 2008-08-28 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| WO2012016695A2 (en) * | 2010-08-04 | 2012-02-09 | Grünenthal GmbH | Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cylohexane-1,1'-pyrano[3,4,b]indol]-4-amine |
| BR112013002734A2 (pt) | 2010-08-04 | 2016-06-07 | Gruenenthal Gmbh | uso de agente farmacologicamente ativo e forma de dosagem farmacêutica |
| RU2589830C2 (ru) | 2010-08-04 | 2016-07-10 | Грюненталь Гмбх | ЛЕКАРСТВЕННАЯ ДОЗИРОВАННАЯ ФОРМА, КОТОРАЯ СОДЕРЖИТ 6'-ФТОР-(N-МЕТИЛ- ИЛИ N, N-ДИМЕТИЛ-)-4-ФЕНИЛ-4', 9'-ДИГИДРО-3'Н-СПИРО[ЦИКЛОГЕКСАН-1, 1'-ПИРАНО[3, 4, b]ИНДОЛ]-4-АМИН |
| CN103179953A (zh) | 2010-08-04 | 2013-06-26 | 格吕伦塔尔有限公司 | 含6’-氟-(n-甲基-或n,n-二甲基-)-4-苯基-4’,9’-二氢-3’h-螺[环己烷-1,1’-吡喃并[3,4,b]吲哚]-4-胺的药物剂型 |
| MX2014000297A (es) | 2011-07-08 | 2014-01-31 | Grünenthal GmbH | (1r,4r)-6´-fluoro-n,n-dimetil-4-fenil-4´,9´dihidro-3´h-espiro[cic lohexan-1,1´-piran[3,4,b]indol]-4-amina cristalina. |
| WO2013087591A1 (en) | 2011-12-12 | 2013-06-20 | Grünenthal GmbH | Solid forms of (1r,4r)-6'-fluoro-(n,n-dimethyl)-4-phenyl-4',9'-dihydro-3'h-spiro-[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and sulfuric acid |
| EP2809307B1 (en) | 2012-01-31 | 2017-12-20 | Grünenthal GmbH | Pharmaceutical patch for transdermal administration of (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4-b]indol]-4-amine |
| US20130202701A1 (en) | 2012-02-03 | 2013-08-08 | Gruenenthal Gmbh | (1r,4r)-6'-Fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4',9'-dihydro-3'H-spiro-[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine for Treating Fibromyalgia and Chronic Fatigue Syndrome |
| US9855286B2 (en) | 2012-05-18 | 2018-01-02 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component |
| US20130310435A1 (en) | 2012-05-18 | 2013-11-21 | Gruenenthal Gmbh | Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol |
| US9320725B2 (en) | 2012-05-18 | 2016-04-26 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid |
| US9345689B2 (en) | 2012-05-18 | 2016-05-24 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant |
| US9320729B2 (en) | 2012-05-18 | 2016-04-26 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative |
| US8912226B2 (en) | 2012-05-18 | 2014-12-16 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r) -6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a NSAR |
| US20130310385A1 (en) | 2012-05-18 | 2013-11-21 | Gruenenthal Gmbh | Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants |
| US9308196B2 (en) | 2012-05-18 | 2016-04-12 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam |
| DK3247352T3 (da) | 2015-01-23 | 2020-09-07 | Gruenenthal Gmbh | Cebranopadol til behandling af smerter hos individer med forringet lever- og/eller forringet nyrefunktion |
-
2016
- 2016-01-22 DK DK16701414.1T patent/DK3247352T3/da active
- 2016-01-22 CN CN201680006851.4A patent/CN107427493A/zh active Pending
- 2016-01-22 JP JP2017538612A patent/JP6673924B2/ja active Active
- 2016-01-22 WO PCT/EP2016/000114 patent/WO2016116280A1/en active Application Filing
- 2016-01-22 CA CA2974578A patent/CA2974578C/en active Active
- 2016-01-22 MX MX2017009416A patent/MX2017009416A/es unknown
- 2016-01-22 TW TW105101958A patent/TW201642853A/zh unknown
- 2016-01-22 EP EP20178446.9A patent/EP3735970B1/en active Active
- 2016-01-22 EA EA201791662A patent/EA201791662A1/ru unknown
- 2016-01-22 AU AU2016208779A patent/AU2016208779B2/en not_active Expired - Fee Related
- 2016-01-22 US US15/545,553 patent/US10022353B2/en active Active
- 2016-01-22 EP EP16701414.1A patent/EP3247352B1/en active Active
-
2017
- 2017-07-02 IL IL253268A patent/IL253268A0/en unknown
-
2020
- 2020-03-04 JP JP2020036768A patent/JP7138300B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018502884A5 (ja) | ||
| Fertonani et al. | Naming facilitation induced by transcranial direct current stimulation | |
| Hummel et al. | Drivers of brain plasticity | |
| CY1111359T1 (el) | Μεμαντινη για την θεραπεια ηπιας εως μετριας ασθενειας alzheimer | |
| EA201000441A1 (ru) | Водные офтальмологические препараты | |
| MA50763A (fr) | Compositions d'acides aminés et méthodés de traitement de maladies et troubles musculaires | |
| EA201491334A1 (ru) | Композиции и способы для лечения метаболических расстройств | |
| MA30287B1 (fr) | Procedes de traitement de maladies inflammatoires et auto-immunes avec du natalizumab | |
| WO2017190044A8 (en) | Methods for detecting and treating pain using brain activity | |
| BR112018070017A2 (pt) | métodos de tratamento de cânceres pediátricos | |
| CY1114688T1 (el) | Ενα γαλακτωμα τυπου νερου μεσα σε λαδι για την θεραπεια μιας ασθενειας του ματιου | |
| BR112013017745A2 (pt) | métodos para o diagnóstico e tratamento de distúrbios relacionados ao comprimento do olho | |
| EA201300314A8 (ru) | Композиции и лекарственное средство для лечения глазных болезней, устройство, содержащее композиции и лекарственное средство | |
| CA2986891C (en) | Compositions for use in treating parkinson's disease and related disorders | |
| WO2008157747A8 (en) | Use of inhibition of exonuclease 1 in methods for therapy and diagnostic of neurodegenerative diseases, eye diseases, and mitochondrial disorders | |
| WO2010018996A3 (ko) | 인간 신경줄기세포 및 이를 이용한 중추 또는 말초 신경계 질환 및 손상 치료용 약학적 조성물 | |
| CA2864606C (en) | Methods of treating and preventing diseases and disorders of the central nervous system | |
| Bolognini et al. | Noninvasive brain stimulation of the parietal lobe for improving neurologic, neuropsychologic, and neuropsychiatric deficits | |
| EA201591021A1 (ru) | 4-гидрокси-2-метил-5-(пропан-2-илиден)циклогекс-3-энекарбальдегид в профилактике и лечении когнитивных, нейродегенеративных или нейронных заболеваний | |
| WO2014100679A8 (en) | Stimulation and enhancement of regeneration of tissues | |
| MA39448A1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical | |
| MX2019004200A (es) | Terapia de combinacion. | |
| DE602006009848D1 (de) | Die regeneration von neuronen des zentralen nervensystems stimulierende peptidsubstanz, darauf basierende pharmazeutische zusammensetzung und verfahren zu ihrer anwendung | |
| RU2612837C1 (ru) | Способ лечения вибрационной болезни, связанной с воздействием локальной вибрации | |
| MX2019013717A (es) | Plasma de origen animal o fracciones del mismo para usarse en el tratamiento contra trastornos del deterioro cognitivo en humanos y animales de compañia. |